The Brazilian pharmaceutical retail sector experienced significant growth in 2025, with revenues reaching R$ 128.6 billion, reflecting a 12% increase compared to the previous year. This growth can be largely attributed to the rising demand for weight loss pens, particularly popular brands like Mounjaro, Ozempic, and Wegovy. The sector has been on a consistent upward trend with an average growth rate of 13% annually, highlighting a shift in consumer preferences towards these innovative pharmaceutical products.

In the ranking of the top five pharmaceutical companies by sales in 2025, Brazilian firms such as NC Farma Corp, Eurofarma, Hypera, and Aché dominate, while the multinational Novo Nordisk climbed to the fifth position, driven by its successful sales of the weight-loss pens. A notable newcomer to the rankings was Eli Lilly, the American manufacturer of Mounjaro, which saw a staggering sales increase of 611% from the previous year, securing the sixth spot in the rankings compiled by Grupo FarmaBrasil based on IQVIA data.

The impact of these weight-loss pens has been evident since 2024, indicating a long-term trend in the market where innovative treatments are reshaping the pharmaceutical landscape in Brazil. This growth not only reflects changing consumer behaviors but also emphasizes the rising importance of biotech and pharmaceutical innovation in addressing health and wellness issues, ultimately affecting the overall structure of the retail pharmaceutical market in the country.